{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:56:38Z","timestamp":1790758598468,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thegreenjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.radonc.2016.09.014","type":"journal-article","created":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T23:15:28Z","timestamp":1478042128000},"page":"310-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Hemi-gland focal low dose rate prostate brachytherapy: An analysis of dosimetric outcomes"],"prefix":"10.1016","volume":"121","author":[{"given":"Robert","family":"Laing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Uribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Horton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Uribe-Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2016.09.014_b0005","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.brachy.2014.01.011","article-title":"Multiparametric MRI identifies and stratifies prostate cancer lesions: implications for targeting intraprostatic targets","volume":"13","author":"Anderson","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2016.09.014_b0010","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.eururo.2010.12.009","article-title":"Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting","volume":"59","author":"Dickinson","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2016.09.014_b0015","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1464-410X.2003.04677.x","article-title":"A brachytherapy template approach to standardize saturation prostatic biopsy","volume":"93","author":"Bott","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2016.09.014_b0020","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/bju.12593","article-title":"Current status of magnetic resonance imaging (MRI) and ultrasonography fusion software platforms for guidance of prostate biopsies","volume":"114","author":"Logan","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2016.09.014_b0025","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.1464-410X.2010.09436.x","article-title":"The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer","volume":"106","author":"Bott","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2016.09.014_b0030","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/pcan.2010.16","article-title":"Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy","volume":"14","author":"Karavitakis","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.radonc.2016.09.014_b0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1464-410X.2011.10825.x","article-title":"Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer","volume":"109","author":"Langley","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2016.09.014_b0040","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.ijrobp.2015.02.043","article-title":"Dosimetry modeling for focal low-dose-rate prostate brachytherapy","volume":"92","author":"Al-Qaisieh","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.09.014_b0045","doi-asserted-by":"crossref","first-page":"f3012","DOI":"10.1136\/bmj.f3012","article-title":"IDEAL framework for surgical innovation 1: the idea and development stages","volume":"346","author":"McCulloch","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2016.09.014_b0050","unstructured":"European Medicines Agency. Guideline for good clinical practice. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002874.pdf> 2006."},{"key":"10.1016\/j.radonc.2016.09.014_b0055","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/bjs.7387","article-title":"Demonstration of the IDEAL recommendations for evaluating and reporting surgical innovation in minimally invasive oesophagectomy","volume":"98","author":"Blazeby","year":"2011","journal-title":"Br J Surg"},{"key":"10.1016\/j.radonc.2016.09.014_b0060","doi-asserted-by":"crossref","first-page":"f2820","DOI":"10.1136\/bmj.f2820","article-title":"IDEAL framework for surgical innovation 3: randomised controlled trials in the assessment stage and evaluations in the long term study stage","volume":"346","author":"Cook","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2016.09.014_b0065","doi-asserted-by":"crossref","first-page":"f3011","DOI":"10.1136\/bmj.f3011","article-title":"IDEAL framework for surgical innovation 2: observational studies in the exploration and assessment stages","volume":"346","author":"Ergina","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2016.09.014_b0070","article-title":"Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use","author":"Barentsz","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2016.09.014_b0075","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.urology.2006.05.033","article-title":"Extensive transperineal template biopsies of prostate: modified technique and results","volume":"68","author":"Bott","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2016.09.014_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1464-410X.2011.10824.x","article-title":"4D Brachytherapy, a novel real-time prostate brachytherapy technique using stranded and loose seeds","volume":"109","author":"Langley","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2016.09.014_b0085","series-title":"Quality assurance practice guidelines for transperieal LDR permanent seed brachytherapy of prostate cancer","author":"The Royal College of Radiologists","year":"2012"},{"key":"10.1016\/j.radonc.2016.09.014_b0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2007.01.014","article-title":"Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO\/EAU\/EORTC recommendations on prostate brachytherapy","volume":"83","author":"Salembier","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.09.014_b0095","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijrobp.2003.11.022","article-title":"Localization of neurovascular bundles on pelvic CT and evaluation of radiation dose to structures putatively involved in erectile dysfunction after prostate brachytherapy","volume":"59","author":"Wright","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2016.09.014_b0100","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.radonc.2008.04.012","article-title":"Novel prostate brachytherapy technique: improved dosimetric and clinical outcome","volume":"88","author":"Nobes","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2016.09.014_b0105","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1016\/j.juro.2007.08.072","article-title":"Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities","volume":"178","author":"Eggener","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2016.09.014_b0110","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.juro.2010.09.099","article-title":"Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy","volume":"185","author":"Stone","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2016.09.014_b0115","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.brachy.2011.08.003","article-title":"Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: the Memorial Sloan-Kettering Cancer Center experience","volume":"11","author":"Zelefsky","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2016.09.014_b0120","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Version 1. 2015."},{"key":"10.1016\/j.radonc.2016.09.014_b0125","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(09)61116-8","article-title":"No surgical innovation without evaluation: the IDEAL recommendations","volume":"374","author":"McCulloch","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2016.09.014_b0130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.brachy.2013.02.002","article-title":"Focal brachytherapy for selected low-risk prostate cancers: a pilot study","volume":"12","author":"Cosset","year":"2013","journal-title":"Brachytherapy"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814016343407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814016343407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T02:22:04Z","timestamp":1536286924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814016343407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0167814016343407"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2016.09.014","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemi-gland focal low dose rate prostate brachytherapy: An analysis of dosimetric outcomes","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2016.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2016 Published by Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}